TLSI
NASDAQ · Biotechnology
Trisalus Life Sciences Inc
$4.34
-0.27 (-5.86%)
Open$4.57
Previous Close$4.61
Day High$4.62
Day Low$4.32
52W High$7.95
52W Low$2.20
Volume—
Avg Volume742.2K
Market Cap283.86M
P/E Ratio—
EPS$-0.59
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
-0.2% upside
Current
$4.34
$4.34
Target
$4.33
$4.33
$2.61
$4.33 avg
$5.56
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 67.64M | 47.23M | 45.65M |
| Net Income | -58,764,473 | -3,256,844 | -3,940,718 |
| Profit Margin | -86.9% | -6.9% | -8.6% |
| EBITDA | -39,428,003 | -4,196,050 | -4,663,249 |
| Free Cash Flow | — | -5,024,799 | -4,621,021 |
| Rev Growth | — | +7.1% | +0.6% |
| Debt/Equity | 0.20 | 1.07 | 0.92 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |